Browse by Audience
Skip to content
Papers of the Week
Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-Dose and Multiple-Dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Abstract
For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a new small-molecule AP2-associated kinase 1 inhibitor with preclinical effectiveness in pain relief.